Any current/future new fundraising through debt or equity?

There is no specific mention of any new fundraising through debt or equity in the provided transcript. The company continues to be debt-free and had cash balances of around INR 691 crores as of June 30, 2024. The management highlighted that they have spent over INR 160 crores on capex recently, funded from internal resources. OrbiMed, an investor holding around 11%, has provided both tangible and intangible benefits including support for exploring M&A targets, but no fresh fundraising was explicitly stated. Plans for acquisitions in the U.S. are underway, but no indication of raising fresh cap

Any current/future capex/capital investment/strategic investment?

The company has incurred a capex of INR 31 crores during Q1 FY'25, aligned with the plan for selling the acquired manufacturing unit in Goa. Over INR 160 crores has been spent on capex recently, indicating significant ongoing investment. The second facility in Goa is ramping up and expected to contribute more than the first facility by the next financial year. The Teva facility is being utilized and there is active planning for backend infrastructure to support growth beyond INR 3,000 crores in revenue, with strategic planning done 2-3 years in advance. No specific new manufacturing acquisitio

Future growth expectations in sales/revenue/volumes?

Marksans Pharma targets growing revenues from INR ~2,100 crores to ~INR 3,000 crores in the next 2 years. The fastest growth driver is expected to be the U.S. market, contributing significantly to reaching INR 3,000 crores. The U.K. market will also add value, bridging the gap but at a relatively slower pace than the U.S. The acquired Teva plant's revenue is increasing month-on-month; expected to hit ~INR 100 crores per quarter by Q3 FY '25. The Goa facilities combined will support expanding production to meet growing global demand. Market penetration into existing U.S. customers, new product

Future growth expectations in earnings/operating earnings/profits/EPS?

The company targets revenue growth from around INR 2,100 crores to INR 3,000 crores over the next two years, driven mainly by the U.S. market with support from the U.K. market. Earnings growth is supported by higher gross margins (expanded by 420+ basis points recently) due to reduced raw material prices and favorable product mix. Operating leverage is expected to improve as the Teva plant scales up production, potentially outweighing increased freight costs. EBITDA margins stood at 21.7% for Q1 FY '25 with expectations to sustain due to operational efficiencies and backward integration benefi

Current/ Expected Orderbook/ Pending Orders?

Current order book is around INR 180 million (Page 11). This order book is executable over the next two years (Page 11). Contracts with customers typically range from two to three years (Page 10). Contracts generally have fixed prices with clauses allowing price renegotiation in case of significant raw material cost escalation (Page 10). The company has good visibility and confidence to reach INR 3,000 crores revenue within the next two years based on the order book (Page 10).

Marksans Pharma LtdQ1 FY25Pharmaceuticals & Biotechnology

Marksans Pharma Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹315.35P/E: 27.7Market Cap: ₹14.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Marksans Pharma targets growing revenues from INR ~2,100 crores to ~INR 3,000 crores in the next 2 years.
The fastest growth driver is expected to be the U.S. market, contributing significantly to reaching INR 3,000 crores.
The U.K. market will also add value, bridging the gap but at a relatively slower pace than the U.S.
The acquired Teva plant's revenue is increasing month-on-month; expected to hit ~INR 100 crores per quarter by Q3 FY '25.
The Goa facilities combined will support expanding production to meet growing global demand.
Market penetration into existing U.S. customers, new product launches, and adding new clients will drive growth.
Future growth levers include deeper penetration in U.K. and exploration of European markets via M&A.
Capacity utilization is expected to increase progressively to meet demand.

Margin guidance

Category 3

The company targets revenue growth from around INR 2,100 crores to INR 3,000 crores over the next two years, driven mainly by the U.S. market with support from the U.K. market.
Earnings growth is supported by higher gross margins (expanded by 420+ basis points recently) due to reduced raw material prices and favorable product mix.
Operating leverage is expected to improve as the Teva plant scales up production, potentially outweighing increased freight costs.
EBITDA margins stood at 21.7% for Q1 FY '25 with expectations to sustain due to operational efficiencies and backward integration benefits.
EPS for Q1 FY '25 was INR 2 with profit after tax up 26.4% YoY, indicating healthy profit growth.
No specific fixed cost increase is anticipated immediately; fixed costs will ramp up proportionately as capacity utilization rises.
Market conditions like freight costs and geopolitical risks remain factors to monitor but currently expected to maintain profitability levels.

See what Marksans Pharma Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no specific mention of any new fundraising through debt or equity in the provided transcript.
The company continues to be debt-free and had cash balances of around INR 691 crores as of June 30, 2024.
The management highlighted that they have spent over INR 160 crores on capex recently, funded from internal resources.
OrbiMed, an investor holding around 11%, has provided both tangible and intangible benefits including support for exploring M&A targets, but no fresh fundraising was explicitly stated.
Plans for acquisitions in the U.S. are underway, but no indication of raising fresh capital via debt or equity was mentioned.
Overall, the company seems focused on organic growth and M&A using existing cash reserves.

Order book

Yes

Current order book is around INR 180 million (Page 11).
This order book is executable over the next two years (Page 11).
Contracts with customers typically range from two to three years (Page 10).
Contracts generally have fixed prices with clauses allowing price renegotiation in case of significant raw material cost escalation (Page 10).
The company has good visibility and confidence to reach INR 3,000 crores revenue within the next two years based on the order book (Page 10).

See what Marksans Pharma Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company has incurred a capex of INR 31 crores during Q1 FY'25, aligned with the plan for selling the acquired manufacturing unit in Goa.
Over INR 160 crores has been spent on capex recently, indicating significant ongoing investment.
The second facility in Goa is ramping up and expected to contribute more than the first facility by the next financial year.
The Teva facility is being utilized and there is active planning for backend infrastructure to support growth beyond INR 3,000 crores in revenue, with strategic planning done 2-3 years in advance.
No specific new manufacturing acquisitions are planned currently, but M&A discussions are ongoing to expand market authorization in Europe without acquiring manufacturing facilities.
The company is exploring capacity augmentation and new land acquisition decisions are under consideration to support growth beyond INR 3,000 crores.

Track Marksans Pharma Ltd — get its next earnings analysis in your feed

How does Marksans Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisMarksans Pharma Ltd

Rev 2Mar 3

See where Marksans Pharma Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Marksans Pharma Ltd rank in Pharmaceuticals & Biotechnology?

Compare Marksans Pharma Ltd against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Marksans Pharma Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →